Browse the evidence

Caffeine consumption reduces total sleep time by an average of 45 minutes and decreases sleep efficiency by 7%, with the magnitude of sleep loss increasing as the dose increases and the time of consumption approaches bedtime.

To protect your sleep, treat caffeine like a timed medication. If you drink a standard cup of coffee (approx. 107mg), stop consuming it at least 8.8 hours before you plan to sleep. If you consume a high-dose pre-workout supplement (approx. 217.5mg), you must stop at least 13.2 hours before bedtime. Consuming caffeine closer to bedtime will significantly reduce your total sleep time and efficiency, regardless of your habitual intake.

Tirzepatide use, particularly with unsupervised dose escalation and caloric restriction, can cause euglycemic ketoacidosis (EKA) in non-diabetic patients.

If you are using tirzepatide, do not self-prescribe or self-escalate doses. Monitor for signs of metabolic acidosis (nausea, vomiting, abdominal pain, fatigue) especially if you are eating very little. Seek immediate medical attention if these symptoms occur, as they can signal euglycemic ketoacidosis, a rare but serious condition.

Tirzepatide treatment in premenopausal women with obesity is hypothesized to increase brown adipose tissue (BAT) volume and activity and induce white adipose tissue (WAT) browning, potentially mitigating the decline in resting energy expenditure typically associated with weight loss.

This paper outlines a clinical trial design, not a consumer guide. It hypothesizes that tirzepatide may help maintain metabolic rate during weight loss by activating brown fat and turning white fat 'beige'. The protocol involves weekly injections starting at a low dose and slowly increasing over 24 weeks, with close monitoring for side effects. No results are available yet.

Semaglutide increases the risk of adverse events, serious adverse events, and discontinuation due to adverse events compared to placebo, primarily driven by gastrointestinal reactions (nausea, diarrhea).

Be aware that semaglutide increases the risk of gastrointestinal side effects like nausea and diarrhea, which can lead to stopping the medication. These side effects are usually temporary and mild to moderate. The risk of discontinuation is higher than with a placebo, so monitoring and managing these symptoms is important for long-term success.

Semaglutide, a long-acting GLP-1 receptor agonist, is hypothesized to reduce arterial stiffness (measured by carotid-femoral pulse wave velocity) and improve cardiometabolic markers in adults with type 1 diabetes.

This paper describes a planned clinical trial, not a finished treatment guideline. It suggests that semaglutide might help people with Type 1 Diabetes who are overweight and have heart risk factors by improving blood vessel stiffness. Patients should discuss this emerging research with their endocrinologist, as the results are not yet available.

Long-term use of semaglutide (GLP-1 RA) may be associated with the development of exocrine pancreatic insufficiency, particularly in patients with concurrent chronic alcohol consumption.

If you are taking semaglutide or similar GLP-1 medications, be aware of potential pancreatic issues, especially if you drink alcohol. Report symptoms like fatty stools (steatorrhea) or abdominal pain immediately. Your doctor should monitor your lipase levels regularly.

SGLT2 inhibitors and GLP-1 receptor agonists provide multi-organ cardiorenal protection beyond glycemic control, with selection prioritized by phenotype (e.g., SGLT2i for heart failure/CKD, GLP-1RA for ASCVD/obesity).

If you have heart, kidney, or metabolic issues, ask your doctor about SGLT2 inhibitors or GLP-1 agonists. These drugs protect your heart and kidneys, not just your blood sugar. Your doctor might even be able to lower your doses of other blood pressure or diabetes pills, reducing your risk of side effects like low blood sugar or dizziness.

Non-steroidal mineralocorticoid receptor antagonists (ns-MRA) like finerenone reduce cardiovascular and renal risks in T2D+CKD patients, with hyperkalemia risk manageable through monitoring.

If you have diabetes and kidney disease, ask about finerenone. It protects your heart and kidneys. Your doctor will check your potassium levels regularly to ensure it is safe for you.

Tirzepatide treatment, particularly during dose escalation, is associated with an increased risk of acute duodenal ulcer perforation in patients with pre-existing untreated Helicobacter pylori infection.

If you are taking tirzepatide and experience persistent or worsening stomach pain, nausea, or vomiting that does not resolve, do not assume it is just a normal side effect. Seek medical attention immediately, especially if you have a history of stomach issues or H. pylori. Early detection of ulcers can prevent perforation.

High-dose tirzepatide (15 mg weekly) can induce severe gastrointestinal side effects (prolonged vomiting and diarrhea) leading to profound electrolyte imbalances (hypokalemia, hypomagnesemia, hypocalcemia), which precipitate life-threatening ventricular fibrillation and cardiac arrest.

If you are on 15mg tirzepatide and have persistent vomiting or diarrhea, do not ignore it. Ask your doctor to check your potassium, magnesium, and calcium levels immediately. Severe GI loss can trigger dangerous heart rhythms even if you have no prior heart history.

Evidence regarding the impact of GLP-1 RAs on total shoulder arthroplasty (TSA) outcomes is limited, heterogeneous, and contradictory, with some studies showing reduced mortality and adverse events while others show increased complications.

For shoulder replacement surgery, the data on GLP-1 RAs is mixed. Some studies show benefits like lower mortality, while others show higher risks of blood clots and pneumonia. Because the evidence is weak and contradictory, your surgical team will likely evaluate your specific case carefully. Do not assume the benefits seen in hip/knee surgery apply here without explicit guidance from your surgeon.

In patients with type 2 diabetes and high cardiovascular risk (CAC ≥ 100), intensified multifactorial treatment using SGLT2 inhibitors and GLP-1 receptor agonists combined with high-intensity lipid-lowering therapy reduces cardiovascular events compared to standard treatment.

If you have Type 2 Diabetes and a high Coronary Artery Calcification (CAC) score (≥100), current standard care may not be enough. This trial tests whether adding specific heart-protective diabetes medications (SGLT2 inhibitors and GLP-1 agonists) along with aggressive cholesterol and blood pressure management significantly reduces your risk of heart attack, stroke, or heart failure compared to standard care. You should discuss your CAC score and whether intensified therapy is appropriate for your specific risk profile with your doctor.

In patients with Type 2 Diabetes and a CAC score of 0 (very low risk), de-escalating multifactorial treatment targets (e.g., less intensive lipid and blood pressure management) is non-inferior to standard treatment regarding cardiovascular events.

If you have Type 2 Diabetes but a Coronary Artery Calcification (CAC) score of 0, your risk of a cardiovascular event is very low (about 1% over 5 years). This trial investigates whether it is safe to reduce the intensity of your cholesterol and blood pressure medications compared to standard care. If your CAC is 0, you might be able to simplify your medication regimen with your doctor, focusing on glucose control and avoiding side effects, without significantly increasing your heart risk.

Semaglutide effectively reverses alectinib-induced excessive weight gain in ALK+ NSCLC patients, though discontinuation due to gallstone pancreatitis can lead to weight regain.

If you are on alectinib and gaining significant weight, semaglutide can help you lose it, but you must get a baseline gallbladder ultrasound first. If you develop abdominal pain, stop the drug immediately as it may cause pancreatitis, which will cause you to regain the weight you lost.

The cardiometabolic benefits of semaglutide 2.4 mg are not maintained after treatment discontinuation, with risk factors deteriorating towards baseline levels.

If you stop taking semaglutide 2.4 mg, the improvements in your blood pressure, blood sugar, and cholesterol will likely reverse towards your pre-treatment levels. This suggests that obesity management with this medication requires long-term, continuous use.

Long-acting GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes, particularly those with established cardiovascular disease or high cardiovascular risk.

If you have type 2 diabetes and are at high risk for heart disease or have existing heart conditions, GLP-1 receptor agonists (like semaglutide or liraglutide) are strongly recommended. These medications not only help control blood sugar but also significantly reduce the risk of heart attacks, strokes, and cardiovascular death. They are considered a standard of care for cardiovascular risk mitigation in this population.

GLP-1RAs reduce the risk of hospitalization for heart failure (HF) and prevent new-onset HF, although they may not reduce readmissions in patients with existing HF.

For patients with type 2 diabetes who are at risk for heart failure, GLP-1RAs can help prevent the initial development of heart failure and reduce the likelihood of being hospitalized for it. However, if you already have heart failure, these medications may not prevent future hospital readmissions, though they still offer other cardiovascular benefits.

Tirzepatide use can cause drug-induced liver injury (DILI) characterized by elevated transaminases, potentially linked to rapid hepatic fat mobilization.

If you are taking tirzepatide and experience unexplained fatigue or abdominal discomfort, ask your doctor to check liver enzymes (ALT/AST). This liver injury is rare and reversible, but monitoring ensures safety. Do not stop the medication without consulting your provider, as the metabolic benefits are significant.

Coadministration of SGLT2 inhibitors and tirzepatide creates a synergistic risk for euglycemic ketoacidosis (EKA), a life-threatening condition characterized by ketone production and acidosis despite normal blood glucose levels.

If you are taking both an SGLT2 inhibitor (like empagliflozin) and tirzepatide, be aware that you are at risk for a rare but serious condition called euglycemic ketoacidosis (EKA). Unlike typical diabetic ketoacidosis, your blood sugar may remain normal, so do not rely on glucose readings alone. If you experience persistent nausea, vomiting, or extreme fatigue, seek medical attention immediately and ask for ketone testing, even if your blood sugar is not high.

Observational studies claiming GLP-1 receptor agonists reduce cancer risk are currently methodologically flawed and cannot support clinical policy due to high risk of bias.

Do not rely on current observational studies to claim that GLP-1 drugs prevent cancer. The existing data is methodologically flawed and cannot yet inform clinical practice or public health policy.

The presence of the rare BDNF p.Thr2Ile variant is associated with a suboptimal response to high-dose tirzepatide treatment, resulting in significantly less weight loss compared to clinical trial averages.

If you have the rare BDNF p.Thr2Ile variant, you might experience less weight loss from tirzepatide than the average patient. Discuss your genetic profile with your doctor to manage expectations and explore alternative treatments.

Antihistaminergic drugs, antipsychotics, fast-release melatonin, ramelteon, and phytotherapeutics are not recommended for insomnia treatment.

Avoid using antihistamines, antipsychotics, fast-release melatonin, ramelteon, or herbal supplements for treating insomnia, as they are not recommended by current guidelines.

Resmetirom is a recommended pharmacotherapy for adults with non-cirrhotic MASH and significant liver fibrosis (stage ≥2), demonstrating histological effectiveness on steatohepatitis and fibrosis.

If you have advanced liver scarring (fibrosis stage 2 or higher) but not cirrhosis, ask your doctor about resmetirom, a medication that can improve liver health.

Caffeine consumption alters sleep architecture by increasing the duration and proportion of light sleep (N1) and decreasing the duration and proportion of deep sleep (N3/N4).

Even if you don't feel tired, caffeine may be stealing your deep sleep. Expect about 11 minutes less deep sleep and 6 minutes more light sleep per night if you consume caffeine close to bedtime. This reduces the restorative quality of your sleep, contributing to next-day fatigue.